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Available online 3 May 2016Identifying the steps involved in striatal development is important both for understanding the striatum in health
and disease, and for generating protocols to differentiate striatal neurons for regenerative medicine. The most
prominent neuronal subtype in the adult striatum is the medium spiny projection neuron (MSN), which consti-
tutes more than 85% of all striatal neurons and classically expresses DARPP-32. Through a microarray study of
genes expressed in the whole ganglionic eminence (WGE: the developing striatum) in the mouse, we identiﬁed
the gene encoding the transcription factor Forkhead box protein P1 (FoxP1) as the most highly up-regulated
gene, thus providing unbiased evidence for the association of FoxP1 with MSN development. We also describe
the expression of FoxP1 in the human fetal brain over equivalent gestational stages. FoxP1 expression persisted
through into adulthood in the mouse brain, where it co-localised with all striatal DARPP-32 positive projection
neurons and a small population of DARPP-32 negative cells. Therewas no co-localisation of FoxP1with any inter-
neuron markers. FoxP1 was detectable in primary fetal striatal cells following dissection, culture, and transplan-
tation into the adult lesioned striatum, demonstrating its utility as an MSN marker for transplantation studies.
Furthermore, DARPP-32 expression was absent from FoxP1 knock-out mouse WGE differentiated in vitro, sug-
gesting that FoxP1 is important for the development of DARPP-32-positive MSNs. In summary, we show that
FoxP1 labels MSN precursors prior to the expression of DARPP-32 during normal development, and in addition
suggest that FoxP1 labels a sub-population of MSNs that are not co-labelled by DARPP-32. We demonstrate the
utility of FoxP1 to label MSNs in vitro and following neural transplantation, and show that FoxP1 is required
for DARPP-32 positive MSN differentiation in vitro.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
FoxP1
DARPP-32
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Neural transplantation
Huntington's disease1. Introduction
Medium spiny neurons (MSNs), which comprise approximately 85%
of striatal neurons in the mouse, are dysfunctional in a number of neu-
rological conditions. In Huntington's disease (HD) MSNs become im-
paired and degenerate over a period of several decades (Harper,osine 3′, 5′- monophosphate-
rotein P1; HD, Huntington's dis-
artin Evans Building, School of
F10 3AX, United Kingdom.
rdiff Metropolitan University,
. This is an open access article under1996). This results in progressive motor, cognitive and psychiatric dis-
turbances leading to progressive decline in functioning over a period
of 20–30 years, eventually necessitating full-time nursing care. Replace-
ment of damaged striatal cells and reconstruction of striatal circuitry is
being actively explored as a therapeutic strategy in this condition
(Kelly et al., 2009). Indeed, both animal studies and pilot human trans-
plantation trials have demonstrated functional beneﬁt of this approach
(Rosser et al., 2011). A fundamental requirement of transplanted cells is
that they accurately differentiate to an MSN phenotype (Precious and
Rosser, 2012); dopamine and cyclic adenosine 3′, 5′- monophosphate-
regulated phosphoprotein, 32 kDa (DARPP-32) has been widely used
as the ‘gold standard’ marker of the terminally differentiated MSN
(Walaas and Greengard, 1984; Tamura et al., 2004). However, DARPP-
32 is not expressed inMSN precursors and is unreliably detected in cul-
ture, perhaps due to insufﬁcient maturity of the emerging post-mitotic
MSNs, and is thus a poor marker of developing MSNs.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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eﬁt in HDare those derived directly fromprimary fetal whole ganglionic
eminence (WGE) (Rosser et al., 2011), the WGE being the structure
from which the striatum develops. However, fetal tissue availability is
limited, and thus there is intense effort to identify a renewable source
of donor cells for cell-replacement strategies, with the most likely
being one ormore sources of stem cells. To date, a small number of pro-
tocols have been published for generatingMSN precursors from human
stem cells (Aubry et al., 2008; Ma et al., 2012; Carri et al., 2013; Arber
et al., 2015). Following transplantation into animal models of HD, de-
spite the presence of DARPP-32 positive neurons in the grafts, all of
these protocols have been found to be associated with deﬁcits in
terms of tissue overgrowth and/or limited functional recovery (Aubry
et al., 2008; Ma et al., 2012; Carri et al., 2013; Arber et al., 2015). This
raises the question as to whether the expression of currently available
markers, including thematureMSN identiﬁer DARPP-32, provides sufﬁ-
cient indication of a population of “genuine” striatal-derived MSNs
(Precious and Rosser, 2012). Thus, there is a pressing need to extend
our understanding of striatal development and to identify well-
validated markers that can indicate the presence of both precursor
andmatureMSNs. As a step in this directionwe carried out amicroarray
study of developing mouse WGE over the period of peak MSN
neurogenesis. Forkhead box protein P1 (FoxP1) emerged as the most
up-regulated gene, and we also demonstrated its expression in the
human fetal WGE over an equivalent period of development. Here, we
show that FoxP1 is amarker ofMSNs from an early progenitor stage, be-
fore the appearance of DARPP-32, right through to adulthood.We dem-
onstrate that it can be used as a marker in both dissociated and
transplanted fetal neural precursors. Furthermore, through the use of
cells from FoxP1 knock-out mice, we demonstrate that the differentia-
tion of the mature DARPP-32 positive MSN phenotype in vitro is depen-
dent on FoxP1.
2. Materials and methods
2.1. Regulated procedures
All animal experiments were performed in full compliance with
local ethical guidelines and approved animal care according to the UK
Animals (Scientiﬁc Procedures) Act 1986 and its subsequent amend-
ments. Human fetal tissue was collected in accordance with the
Polkinghorne and Department of Health guidelines and with full ethical
committee approval as part of the SouthWales Initiative for Transplanta-
tion (SWIFT) program (Kelly et al., 2011).
2.2. Collection of mouse WGE
Mouse WGE was dissected from CD1 pregnant mice (through in-
house breeding). Mated females were checked daily for a vaginal plug.
The day of plug discovery was recorded as embryonic day (E)0. Embry-
onic rodent tissue was dissected according toDunnett et al. (1992). For
microarray and qPCR analysis, tissue was collected at E12, E14 and
E16. WGE tissue was dissected and embryos from each litter were
pooled with 3 litters of each gestational age collected. The accuracy of
dissection was demonstrated by comparing the expression of Gsx2
(predominantly striatal marker) and Pax6 (predominantly cortical
mantle marker) in the presumed WGE and adjacent cortical tissues,
and demonstrated successful identiﬁcation of WGE (unpublished
data). For neural transplantation of wild typemouse allografts, CD1 em-
bryos were taken at E14, dissected WGEs were pooled and aliquots of
cells were transplanted as below.
For collection of mouse FoxP1 knock-outWGE, timemates were set
up between two FoxP1 heterozygote knock-out (FoxP1+/−) mice
(Wang et al., 2004) maintained on a C57BL/6 background. Embryos
were taken at E14, and individual WGE were dissected and collectedseparately from each embryo. WGE from each embryo were processed
individually and a sample of tail was retained for genotyping.
2.3. Collection of human fetal CNS tissue
Human fetal tissue ranging in age from 8 to 12 weeks post concep-
tion (which corresponds to crown rump length of 22–54 mm) was col-
lected according to Kelly et al. (2011). Striatal primordia were dissected
in 0.9% saline solution with addition of 0.6% glucose (Hospital phar-
macy), transferred to Hibernate E (Invitrogen) for overnight storage at
4 °C and processed the following day.
2.4. Gene array process and analysis
RNA extraction was undertaken using TRIzol and RNeasy mini col-
umns (Qiagen) according to the manufacturer's instructions. In vitro
transcription of each RNA sample to antisense biotinylated RNA was
carried out using the BioArray HighYield RNA Transcript Labelling Kit
(Enzo Life Science). Labelled cRNA (15 μg) was hybridised to the
Mouse430A Affymetrix GeneChip Array for 16 h at 45 °C, GeneChips
were washed in an Affymetrix GeneChip Fluidics Station 400 and
scanned with an Agilent GeneArray Scanner. The data were analysed
in the R/Bioconductor environment. Quality control analysis was per-
formed on the arrays (using the “Simpleaffy” package (http://
bioinformatics.picr.man.ac.uk/simpleaffy/)). The array data were nor-
malized using both the MAS5 and RMA algorithms. For each list,
ANOVA tests were performed. The Tukey-Kramer post-hoc test was
used to determine any signiﬁcantly differentially expressed genes at a
false discovery rate (FDR) of 5%. The lists of signiﬁcantly differentially
expressed genes were then analysed for speciﬁc patterns of gene en-
richment using the GSA package (http://www-stat.stanford.edu/~tibs/
GSA/), using gene ontology (GO) probeset annotations that were ob-
tained from the molecular signatures database (http://www.
broadinstitute.org/gsea/msigdb/index.jsp). All microarray raw data
can be found online at GEO (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=ovepqugwtlmftuj&acc=GSE55497) (GSE55497).
2.5. Quantitative RT PCR (qPCR)
cDNAs were generated from the same RNA samples used above
using Superscript II Reverse Transcriptase (Invitrogen) and qPCR was
performed using SYBR green (Finnzymes) and an Opticon Monitor 2
system. qPCR conditions were 95 °C for 15 min, followed by 41 cycles
of 95 °C for 30 s, 60 °C for 30s and 72 °C for 30 s. Each qPCR was per-
formed in triplicate, and relative quantiﬁcation against Gapdh was de-
termined according to the ΔΔC(t) method (Livak and Schmittgen,
2001). For analysis of data, the software Opticon Monitor 3 was used
(Biorad) and statistical analysis was carried out using SPSS 16.0. Primer
sequences were as follows: mouse FoxP1 CAGCCACCCTCTCTATGGAC
and AGCGCATGCTCACTGTTG; and human FoxP1 GCAGTTACAGCAGC
AGCACCTCC and CAGCCTGGCCACTTGCATACACC.
2.6. In situ hybridisation (ISH)
Frozen heads of CD1mice (E12, E14, E16, postnatal day (P)0, P7 and
adult) or human fetal brains (8–12weeks post conception, crown rump
length range 22–54 mm) were sectioned at 30 μm using a cryostat,
mounted onto Superfrost charged slides and ﬁxed with 4% paraformal-
dehyde in phosphate buffer. Sectionswere treated and hybridised over-
night with DIG-labelled riboprobes at 58 °C. Following overnight
hybridisation, the slides were washed then blocked for 1 h. After
blocking, alkaline phosphatase-conjugated anti-DIG antibody (1:1500;
Roche Applied Sciences) was applied for 1 h followed by washing and
then developing with NBT/BCIP (Roche) in alkaline phosphatase buffer.
All slides were visualised using Wild Heerbrugg Makroskop M420 mi-
croscope and MagnaFire 2.1C software.
Table 1
Gene array probes for Forkhead box protein P1 (FoxP1).
Gene index E12–E14 E14–E16 E12–E16 FDR
corrected
p-value
Log2
FC
Abs
FC
Log2
FC
Abs
FC
Log2
FC
Abs
FC
1421141_a_at −2.0 4.1 −1.3 2.5 −3.3 10.1 0.003
1435221_at −2.0 4.1 −1.0 2.1 −3.1 8.3 0.002
1435222_at −1.9 3.6 −1.2 2.2 −3.0 8.1 0.004
1455242_at −1.9 3.6 −1.0 2.0 −2.9 7.3 0.005
1421140_a_at −1.6 3.0 −1.0 2.0 −2.6 5.9 0.003
1421142_s_at −1.4 2.6 −1.2 2.2 −2.5 5.7 0.002
1438802_at −1.1 2.1 −1.2 2.3 −2.3 4.9 0.028
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tracted RNA (forward mouse primer: ATGCTGGAAAACAGCCGAAA, re-
verse mouse primer: GTGCTCCTCGTGGGACAAG; and forward human
primer: GCAGTTACAGCAGCAGCACCTCC, reverse human primer: CAGC
CTGGCCACTTGCATACACC), whichwere inserted into the cloning vector
pCRIItopo (Invitrogen). The site of insertion is ﬂanked by RNA polymer-
ase initiation sites; SP6 and T7 thus allowing for sense and antisense
strands to be synthesised. All probes were labelled with DIG (Roche).
No staining was seen in any of the sections exposed to the sense probe.
2.7. In vitro differentiation
For mouse tissue, dissected WGE pieces (from E14 embryos) were
transferred to 0.1% trypsin (Worthington, New Jersey, USA) and 0.5%
DNAse (Sigma, Dorset, UK) in Hank's balanced salt solution (HBSS) for
20 min at 37 °C. Trypsin inhibitor 0.01% (Sigma) and DNAse 0.05% were
added and the tissue was incubated for a further 5 min at 37 °C. Tissue
was then washed in DMEM/F-12 (Invitrogen), centrifuged at 1000 rpm
for 3 min and the remaining pellet was resuspended in 200 μL DMEM/
F-12 and triturated 10–15 times with a 200 μL Gilson pipette to generate
a single-cell suspension. Cells were counted using a haemocytometer and
trypan blue (Sigma) exclusion was used to assess cell viability.
For human tissue, dissected striatal pieces were incubated in equal
volumes of TrypLE express (Invitrogen) and Benzonase (1:10,000)
(Merck, UK) for 20 min at 37 °C. Tissue was then washed in saline-
glucose solution, centrifuged at 1000 rpm for 3 min and the remaining
pellet was resuspended in 200 μL DMEM/F-12 and triturated 10–15
times with a 200 μL Gilson pipette to generate a single-cell suspension.
Cells were counted and viability assessed (as above).
For in vitro differentiation of both mouse and human cells, dissoci-
ated cells were plated onto 13 mm glass coverslips coated with poly-L-
lysine at a density of 50,000 cells per well in a 30 μL drop of differentia-
tionmedium (DMEM/F-12, 1% PS, 2% B-27 (Invitrogen) plus 1% fetal calf
serum (FCS) (Invitrogen)) and were allowed to adhere for 2–3 h before
the wells were ﬂooded with a further 500 μL differentiation medium.
Cultures were maintained at 37 °C in humidiﬁed 5% CO2 and 95% atmo-
spheric air, and differentiation medium was replaced with fresh me-
dium every 2–3 days. Cultures were allowed to differentiate for 7 or
14 days. Cells were then washed in phosphate-buffered saline (PBS)
(Invitrogen) and ﬁxed in 4% paraformaldehyde in PBS for 20 min.
2.8. Immunohistochemical analysis of in vitro differentiated cells
Fluorescent immunocytochemistry followed standard protocols
with primary antibodies for rabbit anti-FoxP1 (1:500; Abcam), mouse
anti-FoxP1 (JC12) (1:500; Abcam), mouse anti-β-III-tubulin (1:1000;
Sigma), mouse anti-Map2ab (1:500; Sigma), mouse anti-DARPP-32
(1:20,000; a gift from Prof H. Hemmings), mouse anti-GFAP (1:500;
Abcam), rabbit anti-GAD65/67 (1:2000; Millipore), rabbit anti-met-
enkephalin (1:15,000; Millipore), rat anti-CTIP2 (1:500, Abcam) and
rat anti-BrdU (1:200, Oxford Bio). For double labelling, the two primary
antibodies that had been raised in different species were added at the
same time. Appropriate ﬂuorescent-labelled secondary antibodies
(Life technologies) were applied, followed by the nuclear stain Hoechst.
Fluorescent staining was visualised using a Leica DRMBE microscope at
560 nm (red), 494 nm (green) and 346 nm (blue). Cell counts were un-
dertaken at 40×magniﬁcation using a counting grid. For unbiased sam-
pling, 5 ﬁelds were chosen at random from which to take counts.
Pseudocolour ﬂuorescent images were obtained using Openlab 2.1
image analysis software and colour images were processed using
Adobe Photoshop.
2.9. Immunohistochemical analysis of whole brain sections
Sections were processed for immunohistochemistry using the free-
ﬂoating, biotin-streptavidin-horseradish peroxidise method withprimary antibodies for anti-FoxP1 (as above), mouse anti-DARPP-32
(as above except at 1:10,000), mouse anti-NeuN (1:4000; Chemicon),
mouse anti-parvalbumin (1:4000; Sigma), mouse anti-Nkx2.1 (TTF1;
1:500; DAKO) and rat anti-CTIP2 (as above). Stained sections were
visualised using a Leica DRMBE microscope and images were obtained
usingOpenlab 2.1 image analysis software. Anatomical areaswere iden-
tiﬁed using the Interactive AtlasViewer of theAllen BrainAtlasWebsite:
2015 Allen Institute for Brain Science. Allen Mouse Brain Atlas [Inter-
net]. Available from: http://mouse.brain-map.org and Allen Developing
Mouse Brain Atlas [Internet]. Available from: http://developingmouse.
brain-map.org.
2.10. Quinolinic acid striatal lesions and neural transplantation
Quinolinic acid is a relatively selective MSN toxin, sparing most of
the interneuron populations (Schwarcz and Kohler, 1983; Schwarcz
et al., 1983; Beal et al., 1986). Animals (CD1 mice and Sprague-Dawley
rats) received unilateral injection of 45 nmol quinolinic acid into the
right striatum, and transplantation was carried out at 10–14 days
post-quinolinic acid lesion as per Kelly et al. (2007). For mouse E14
WGE transplants into the host adult mouse lesioned striatum, 250,000
cells were resuspended in 2 μL and stereotactically injected over
2 min. For humanWGE transplants into the host adult rat lesioned stri-
atum, 500,000 cells were resuspended in 2 μL and stereotactically
injected over 2 min.
Animals were housed in a natural light-dark cycle with access to
food and water ad libitum. All surgery was performed under isoﬂuorane
anaesthesia and post-surgery animals were recovered in a warmed re-
covery chamber and received analgesia by Metacam (Boehringer
Ingelheim). All animals were perfused transcardially and ﬁxed using
1.5% paraformaldehyde solution before the brains were removed,
post-ﬁxed overnight and transferred to 25% sucrose for cryoprotection.
Brains were sectioned at 40 μm on a freezing-stage microtome and sec-
tions were stored for subsequent histological analysis.
2.11. Statistics
All data were analysed using one-way ANOVA with Tukey-Wallis
post-hoc test and Student's t-test with signiﬁcance set at 0.05.
3. Results
3.1. FoxP1 expression is highly up-regulated during striatal neurogenesis
and is maintained to adulthood where it is expressed in MSNs
To identify genes whose expression is associatedwith striatal devel-
opment a microarray analysis of mouse WGE from E12, E14 and E16
embryos was performed, thus covering the period before, during and
after peak striatal neurogenesis (van der Kooy and Fishell, 1987;
Deacon et al., 1994; Olsson et al., 1995). The full Affymetrix array data
are available online at gene expression omnibus (GEO datasets, NCBI).
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Fig. 2. FoxP1 expression in the adultmouse intact and quinolinic acid-lesioned striatum. Immunohistochemistry revealed expression of DARPP-32 (A) and FoxP1 (B) throughout the intact
adult striatum (left-hand side of the brain). Following striatal quinolinic acid-lesion, expression of both DARPP-32 (A) and FoxP1 (B) is lost within the lesioned area of the striatum (right-
hand side of the brain). The lower panels show higher magniﬁcation of the striatal areas.
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mouseWGE between E12 and E16, and revealed that FoxP1 was signif-
icantly up-regulated between these ages (Table 1). Themouse microar-
ray used in this study had 7 FoxP1 probesets and there was high
representation of the FoxP1 probesets in the most up-regulated se-
quences with FoxP1 appearing 4 times in the top 10, and 7 times in
the top 70 probes, based on fold change. Validation of FoxP1 up-
regulation was obtained by qPCR analysis of E12, E14, and E16 WGE
per unit of tissue relative to GAPDH (Fig. 1A), with an overall signiﬁcant
increase in expression of FoxP1 (F2,9 = 98.78, p b 0.001).
We then analysed the spatial distribution of FoxP1 at the time points
corresponding to those used for the microarray analysis using ISH
(Fig. 1B). At E12 expression was restricted to the WGE and absent
from the adjacent subventricular proliferative zone. Expression was
maintained in theWGE at E14 and E16 as this structure continues to in-
crease in size. By E14 and E16 some staining is also seen in the develop-
ing neocortex.
Immunohistochemistry using FoxP1 antibodies in embryonic
brain sections demonstrated the presence of FoxP1 protein over
the same developmental time period (Fig. 1C-E). Analysis of
FoxP1 protein expression was extended into the postnatal period
where continued presence of FoxP1 was found in the striatum at
P0 and P7 and in the adult striatum (Fig. 1F–K). Fig. 1L–N shows
double immunohistochemistry in the adult striatum, which demon-
strated that FoxP1 co-localised with both the neuronal marker
NeuN (Fig. 1L) and the MSN marker DARPP-32 (Fig. 1M). However,
it did not co-localise with a range of interneuron markers (shown
for parvalbumin in Fig. 1N). Cell counts within the adult striatum
revealed that 100% of FoxP1 positive cells co-labelled with NeuN,
although not all striatal NeuN positive cells were FoxP1 positive.
100% of DARPP-32 positive cells co-labelled with FoxP1, but only
86% of FoxP1 positive cells were also DARPP-32 positive. Thus,
this reveals a population of FoxP1 positive/DARPP-32 negativeFig. 1. FoxP1 expression in the mouse striatum. Up-regulation of FoxP1 during striatal developm
(A). ISH photomicrographs demonstrate increasing signal intensity and spatial distribution of
proliferative zone, and there is lower level intensity staining in the cortical plate (B). Photom
expression pattern as shown with ISH in the mouse WGE at E12 (C), E14 (D) and E16 (E). Fox
(F and higher power I), P7 (G and higher power J) and adulthood (H and higher po
immunohistochemical double-staining for FoxP1 (grey)/NeuN (brown), arrow shows doubl
arrow head shows FoxP1 positive cell/DARPP-32 negative cell (M); and a lack of double stainin
(A) *** = p b 0.001.cells in the striatum not hitherto reported. To date we have not
been able to identify a speciﬁc neuronal phenotype marker (includ-
ing striatal interneuron markers) that identiﬁes this FoxP1 positive/
DARPP-32 negative population.
To conﬁrm the association of FoxP1withMSNs in the adult striatum,
quinolinic acid was used to ablate DARPP-32 positive MSNs (Beal et al.,
1986; Davies and Roberts, 1987, 1988). A complete loss of DARPP-32
and FoxP1 in the centre of the quinolinic acid-lesioned area was found
(Fig. 2A and B). This demonstrates that the ablation of MSNs, which is
associated with a profound loss of DARPP-32 expression, is accompa-
nied by an equivalent loss of FoxP1, thus supporting the notion that
FoxP1 selectively labelsMSNs in the adult striatum. It is also further con-
ﬁrmation that FoxP1 is not expressed in interneurons, as these are
largely spared following the quinolinic acid infusion.
3.2. FoxP1 expression is maintained in dissociated primary fetal WGE pre-
cursors in vitro
A critical element of neural transplantation protocols is that
donor cells are dissociated and suspended in medium in order to
be injected into the CNS. Having seen FoxP1 expression in the in-
tact developing brain, we wished to analyse FoxP1 expression in
cells that have been dissected, dissociated, and placed in cell cul-
ture. To investigate whether the expression of FoxP1 is maintained
in differentiating cell cultures, mouse neural cells from wild type
embryos at E14 were assessed after seven days differentiation
in vitro (Fig. 3). FoxP1 positive cells were detected in dissociated
cultured WGE (Fig. 3A) and cortex (Fig. 3B), but not in ventral
mesencephalon (Fig. 3C) or dorsal mesencephalon (data not
shown). The FoxP1 immunopositive WGE cells were identiﬁed as
neuronal because they co-labelled at early time points in culture
with the neuronal marker β-III-tubulin (which is expressed from
the start of neuronal maturation), and also with the more matureent in the mouse brain between the ages E12 and E16 was validated using qPCR analysis
FoxP1 expression in the region of the WGE from E12 to E16, but not in the subventricular
icrographs of immunohistochemical staining for FoxP1 protein demonstrate a similar
P1 protein expression in mouse brain persists within the striatum through to birth (P0)
wer K). The lower panel of photomicrographs shows adult mouse striatum with
e-labelled cell (L); FoxP1 (grey)/DARPP-32 (brown), arrow shows double-labelled cell,
g with parvalbumin (brown; arrow) and FoxP1 (grey; arrow head) (N). For the graph in
Fig. 3.Characterisation of FoxP1 expression inmouse cell culture.Mouse neural tissue fromdifferent brain regionswas differentiated for 7 days and immunostained for FoxP1 (A–C). FoxP1
expression (green) was seen in cells from theWGE (A) and the cortex (B), but no expression was seen in cells form the ventral mesencephalon (C). MouseWGE differentiated for 7 days
in vitro, labelled for FoxP1 (green), which co-expressed the immature neuronal marker β-III-tubulin (red) (D) and the moremature neuronal markerMap2ab (red) (E). There was no co-
expression of FoxP1with the glial marker GFAP (red) (F). FoxP1 positive cells (green) co-expressed themature striatal MSNmarker DARPP-32 (red) (G), the GABAergic neuronal marker
GAD-65/67 (red) (H) and the striatal neuronal marker met-enkephalin (red) (I). Nuclei were labelled with Hoechst (blue). Scale bar = 20 μm.
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(Fig. 3D-F). Furthermore, these neurons were identiﬁed as the
MSN population of cells in these primary fetal mouse cultures
through co-localisation of FoxP1 with the striatal MSN marker
DARPP-32, the GABAergic neuronal marker GAD-65/67 and the
striatal projection neuron marker met-enkephalin (Fig. 3G–I). Nota-
bly, as we found in the intact adult brain, although all DARPP-32
immunopositive cells co-expressed FoxP1 there were more FoxP1
immunopositive cells than DARPP-32 immunopositive cells (FoxP1:
40.2 ± 4.0% (mean ± SEM) as a percentage of total cells, and
DARPP-32: 8.8 ± 1.0% as a percentage of FoxP1). As mentioned
above, the relatively low percentage of DARPP-32 expression in cul-
tured WGE is a common ﬁnding that compromises its use as an
MSN marker in vitro. This ﬁnding probably reﬂects the relative im-
maturity of the cells in vitro. Our interpretation is that FoxP1 labels
MSN precursors thus emphasising its utility as a marker of these
cells in culture.
3.3. FoxP1 is expressed in human fetal WGE
Having established that FoxP1 is expressed in murine MSNs, both
in vivo and in vitro, we next assessed FoxP1 expression in human WGE
at equivalent developmental windows. We analysed spatial expression
using ISH on sections from two fetal brains of 26mmand 52mm crown
rump length (equivalent to approximately 8 weeks and 12 weeks post-
conception, respectively, Fig. 4A and B). These show the anatomicaldistribution of FoxP1 to be in the WGE, and not in the adjacent
subventricular proliferative zone. As described above for the mouse,
FoxP1 expression was detected in the developing cortical region in the
older embryo. qPCR demonstrated FoxP1 expression in 8 separate
human fetal striatal tissue samples ranging from 22 to 54 mm crown
rump length (equivalent to 8–12 weeks post conception) (data not
shown). Immunohistochemical analysis of human fetal brain sections
for FoxP1 revealed co-localisation with Coup TF1-interacting protein 2
(CTIP2) (conﬁned to the LGE portion of the developing striatum), but
no co-localisation with Nkx2.1 (a classic medial ganglionic eminence
marker) (Fig. 4C andD). This provides evidence that the spatial distribu-
tion of FoxP1 in the human WGE is similar to the mouse at equivalent
developmental stages. Furthermore, FoxP1 was detected in human
fetal WGE dissociated cells differentiated for 14 days in vitro. Here it
co-localised with MAP2ab and DARPP-32; all DARPP-32 positive cells
were seen to be FoxP1 positive (Fig. 4E-G), but again, not all FoxP1 pos-
itive cells co-expressed DARPP-32. Thus, as in the mouse, we suggest
that FoxP1 labels immature MSN precursors that have been dissociated
and placed in culture.
3.4. FoxP1 expression is maintained in primary fetal WGE precursors
transplanted into the quinolinic acid-lesioned striatum
The ultimate preclinical test for cells differentiated to an MSN phe-
notype for a therapeutic purpose is to transplant them into an animal
model of HD. Therefore, for FoxP1 to be a useful marker in this context,
Fig. 4. FoxP1 expression in human fetal striatal samples. FoxP1 expression in human fetal brain was assessed using ISH. Two human fetal brain samples were used: crown rump length
26 mm (A) and 52 mm (B). At the earlier time point (crown rump length 26 mm) FoxP1 expression is seen exclusively within the developing striatum (A); by crown rump length
52 mm, FoxP1 expression is visible in the developing cortical region as well as the developing striatum (B). Merged photomicrographs of immunoﬂuorescence carried out on human
fetal brain sections from an embryo measuring 48 mm crown rump length (C) and higher power of the boxed area in (C) shown in (D). FoxP1 (red) co-localised with CTIP2 (grey) in
the LGE but did not co-localise with Nkx2.1 (green) in the MGE portion of the developing striatum. FoxP1 and CTIP2 double-labelled cells appear white (D). Dashed line in C
demarcates the border between the LGE and MGE. Cell nuclei labelled with Hoechst (blue). HumanWGE differentiated for 14 days in vitro expressed FoxP1 (green) (E); FoxP1 positive
cells (green) co-labelled with Map2ab (red) (F); the small number of DARPP-32 positive cells (red) seen co-localised with FoxP1 (green) (G); arrows (in F and G) indicate examples of
double-labelled cells. Nuclei were labelled with Hoechst (blue). Scale bar (E–G) = 100 μm.
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ated WGE cells into the adult brain. To assess FoxP1 expression post-
transplantation, E14 mouse WGE cells were transplanted into the le-
sioned side of the mouse host striatum 10–14 days post-unilateral
quinolinic acid-lesion. FoxP1 was expressed within the graft area at
the ﬁrst time point assessed, which was 4 weeks post-transplantation
and was still present at 12 weeks, with no signiﬁcant difference in the
numbers of FoxP1 positive cells within the grafts at the two survival
times (796 ± 144 and 764 ± 276 respectively; t2 = 0.10, p = n.s;
shown for 4weeks in Fig 5A).We then askedwhether FoxP1 expression
was alsomaintained following transplantation of humanWGE cells into
the quinolinic acid-lesioned rat striatum. Fig 5B shows FoxP1 cells in the
graft area at 20weeks post-transplantation. Calculation of graft volumes
revealed 0.4 ± 0.1 mm3 for the mouse-to-mouse transplants, and
13.9± 0.9mm3 for the human-to-rat transplants. These results demon-
strate that there is continued expression of FoxP1 post-transplantation
as the cells differentiate and integrate into the host striatum, supporting
the notion that FoxP1 is a reliable marker of developing and mature
MSNs for cell replacement studies.3.5. FoxP1 is required for the production of DARPP-32-expressing striatal
MSNs
The previous experiments have demonstrated that FoxP1 is
expressed in MSNs from progenitors through to maturity in a
range of situations including those relevant for cell transplantation
studies. We then wished to ask whether FoxP1 is necessary for
the differentiation of DARPP-32 positive MSNs. This question was
addressed by using cells from a FoxP1 knockout mouse (Wang
et al., 2004). There is loss of FoxP1 expression in the homozygous
knockout (FoxP1−/−) WGE, and intermediate levels in the hetero-
zygous knockout (FoxP1+/−) WGE (Fig. 6A-C). The effect of FoxP1
loss was assessed by comparing the in vitro differentiation of E14
WGE cells derived from FoxP1−/−, FoxP1+/− and wild type em-
bryos. E14 tissue was used as it is the embryonic stage routinely
used for striatal transplantation experiments. E14 is also prior to
the in utero death of FoxP1−/− embryos, which occurs at E16.
Loss of FoxP1 did not appear to affect numbers of neurons (as in-
dicated by β-III-tubulin) or proliferation (according to BrdU
Fig. 5. FoxP1 expression post-transplantation. Following transplantation ofmouseWGE-derived precursors into the adultmouse quinolinic acid-lesioned striatum, FoxP1 protein (brown)
is shown at 4 weeks post-transplant (A). Human fetal WGE-derived precursors transplanted into the adult rat quinolinic acid-lesioned striatum identiﬁed FoxP1 positive cells (green) at
20 weeks post transplantation (B). Scale bar (A) = 100 μm.
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expression were signiﬁcantly reduced in the FoxP1−/− cultures
(Fig. 6D-F). There was no signiﬁcant difference between wild type
and FoxP1+/− cultures with respect to DARPP-32 and CTIP2 expres-
sion (Fig. 6D-F).
In summary, cells lacking FoxP1 are substantially compromised in
their ability to differentiate into cells that express the MSN marker
DARPP-32, strongly suggesting that FoxP1 is required for thenormal dif-
ferentiation of these neurons.
4. Discussion
We present evidence that FoxP1 is a valuable marker of both undif-
ferentiated andmatureMSNs and, signiﬁcantly, that FoxP1 is suitable to
recognise these cells in transplant paradigms. Furthermore, we have
shown that DARPP-32 positive MSNs fail to develop in the absence of
FoxP1, indicating that FoxP1 is important for the normal differentiation
of striatal MSNs.
Microarray analysis allows an unbiased assessment of gene expres-
sion change and using this approach we found that FoxP1 is the most
prominently up-regulated gene during peak striatal neurogenesis in
the mouse. ISH between E12 and E16 in the mouse revealed intense
FoxP1 staining in theWGE and also expression in the cortex, and similar
ﬁndings were evident in the human over an equivalent developmental
window. We further showed FoxP1 protein expression in the WGE
and also demonstrated its continued presence into the neonatal period
(P0 and P7) aswell as in the adult striatum. The ﬁnding of FoxP1 in both
fetal and adult brain is consistent with previous studies (Ferland et al.,
2003; Tamura et al., 2003, 2004; Arlotta et al., 2005; Hisaoka et al.,
2010; Urban et al., 2010; Allen Mouse Brain Atlas; Allen Developing
Mouse Brain Atlas), although demonstration of persistent expression
in neonatal brain has not been previously reported.
In our study, the majority of neurons in the adult mouse striatum
were FoxP1 positive, and all DARPP-32 positive cells co-labelled with
FoxP1, suggesting that FoxP1 labels all MSNs. Our study is consistent
with the ﬁnding of Arlotta et al, who reported that FoxP1 in the
mouse striatum co-labelled entirely with CTIP2, which in turn co-
labelled with all DARPP-32 positive cells (Arlotta et al., 2008). Interest-
ingly, we also revealed a population of FoxP1 positive/DARPP-32 nega-
tive cells. The absence of any co-labelling of FoxP1with any interneuron
marker is in agreement with Arlotta et al. (2008) and makes it unlikely
that these cells are interneurons. Thus, although their identity is not
known, we believe that this population is most likely to be either
MSNs that do not express DARPP-32 or non-MSN projection neurons.
Further evidence for the association of FoxP1with striatalMSNs, and
not interneurons, comes from the demonstration that FoxP1 expression
is completely lost in the quinolinic acid-lesioned mouse striatum. Thiswas the case, not only in the centre of the lesion where, it could be ar-
gued, the highest concentrationsmay result in loss of some interneuron
populations, but also in the penumbra of the lesionwherewewould ex-
pect selective loss ofMSNswith relative sparing of interneurons (Davies
and Roberts, 1987, 1988). This further strengthens the validity of FoxP1
as anMSNmarker. Furthermore, the complete loss of DARPP-32 expres-
sionwith concurrent loss of all FoxP1 supports the notion that the FoxP1
positive/DARPP-32 negative population are either DARPP-32 negative
MSNs or non-MSN projection neurons.
Given the strong association of FoxP1 with MSNs from their birth
through to adulthood, we suggest that FoxP1 is a valuable marker of
both mature MSNs and their progenitors. In the developing mouse
brain, DARPP-32 mRNA is undetectable at E14, and even by P0 both
DARPP-32 mRNA and protein are present only in very small amounts
(unpublished observation and Ehrlich et al., 1990). In contrast to
FoxP1, thismakes DARPP-32 poorly suited to detectingMSN precursors,
and also explains the low percentage of DARPP-32 positive neurons re-
ported in the differentiated cultures here and elsewhere.
There are a number of applications of this increased understanding
of FoxP1 in striatal development. The practical use of FoxP1 as an MSN
marker in fetal WGE transplantation for HD requires that it continues
to be expressed in MSN precursors following dissociation and culture
of the donor cells and once such cells are transplanted into the adult
striatum. Here we have shown that FoxP1 is expressed in dissociated
cultured mouse and human WGE, exclusively in neurons and co-
localisedwith known striatal markers, including DARPP-32. For the rea-
sons discussed above, the proportion of DARPP-32 positive cells in cul-
tured WGE was low, but nevertheless all the DARPP-32 positive cells
co-expressed FoxP1. Similarly, fetal WGE from both mouse and
human transplanted into the quinolinic acid-lesioned striatum also
expressed FoxP1. This provides the basis for the use of FoxP1 as a
marker of MSN precursors in such transplantation studies.
For the generationof donor cells from stem cell sources, the poor and
unreliable staining of DARPP-32 in vitro is also a signiﬁcant problem.
Generation of precursors capable of producing an authentic MSN phe-
notype is critical to the success of transplantation therapy in HD
(Rosser et al., 2011; Evans et al., 2012; Precious and Rosser, 2012). To
date most such protocols require multiple steps over many days
in vitro, and the ability to identify partially speciﬁed MSN precursors
prior to DARPP-32 expression is a distinct advantage. However, despite
themany advantages of using Foxp1 for labelling precursor andmature
MSNs, in common with other striatal markers (such as CTIP2 and
DARPP-32), it is also found extrastriatally in developing and adult
brain (Ferland et al., 2003; Hisaoka et al., 2010; Allen Developing
Mouse Brain Atlas; Allen Mouse Brain Atlas; our unpublished ﬁndings).
Thus, its most powerful use will be in combination with other MSN
markers.
Fig. 6. FoxP1 expression in the control and knock-out mouse brain and with in vitro analysis after 7 days in culture. FoxP1 immunohistochemical analysis of E14 fetal mouse brain
demonstrates FoxP1 expression in the WGE of wild-type (WT) controls (A) and lack of staining in the knock-out mutant (FoxP1−/−) (B); lower panels show areas of higher
magniﬁcation (A–B). RT-PCR of E14 fetal WGE conﬁrms lack of FoxP1 in homozygous embryos (FoxP1−/−) and intermediate levels in the heterozygous embryos (FoxP1+/−) (C). E14
mouse WGE cultures from each of the three genotypes were differentiated for 7 days. Following ﬁxation cells were double labelled for Foxp1 (red) and β-III-tubulin (green), DARPP-
32 (green) and CTIP2 (red). BrdU (red) was also added 24 h prior to ﬁxing to assess proliferation (D). Cells were counted and are represented as a percentage of total Hoechst positive
nuclei (E and F). FoxP1 expression was lost in the FoxP1−/− cultures, with no accompanying loss of neuronal numbers. DARPP-32 expression and CTIP2 expression were signiﬁcantly
reduced in the FoxP1−/− cultures, with intermediate levels for the FoxP+/− cultures. There was no signiﬁcant difference in BrdU expression. Scale bars (D) = 50μm. Each bar on the
graphs represents a mean of at least 3 cultures from different embryos and error bars are SEM. Signiﬁcant post-hoc differences are indicated with brackets (ANOVA with Tukey-Wills
post-hoc test, ***p b 0.001, *p b 0.05).
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will facilitate the optimisation of protocols more likely to produce dif-
ferentiated cells with a full complement of MSN features. The strikingexpression of FoxP1 associated with MSN differentiation suggests that
FoxP1 might be an important element in the MSN differentiation path-
way. We addressed this by analysing the effect of FoxP1 loss on the
18 S.V. Precious et al. / Experimental Neurology 282 (2016) 9–18differentiation of MSNs using WGE cells from FoxP1 knock-out E14
mouse embryos (FoxP1−/−). The lack of DARPP-32 staining in these
cells cultured in vitro strongly implicates FoxP1 as a key element in
the differentiation of DARPP-32 positive MSNs. Intriguingly, expression
of another transcription factor associatedwithMSN identity, CTIP2, was
reduced but not completely abolished. This raises the question as to the
identity of the remaining DARPP-32 negative/CTIP2 positive cells. Full
characterisation will require detailed analysis of transplanted FoxP1
knock-out cells to allow maturation beyond what can be achieved
in vitro, with accompanying analysis of their capacity to undertake any
of the functions of the normal MSN population.
In summary, we have presented evidence that FoxP1 is a valuable
marker of immature MSNs from an early developmental stage in the
mouse, and continues to identify this population throughout life. We
also demonstrated the utility of FoxP1 as a marker in both cultured
and transplanted MSNs both from mouse and from human. Lastly, the
strong association of FoxP1 with differentiating MSNs, and the reduc-
tion of DARPP-32 positive cells in cultured FoxP1 knock-out WGE
cells, strongly suggests that it has an important role in MSN
differentiation.
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